FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W829113430> ?p ?o ?g. }

• W829113430 endingPage "1929" @default.
• W829113430 startingPage "1911" @default.
• W829113430 abstract "Background: The elevated risk of heart failure (HF) in rheumatoid arthritis (RA) is considered to be partly caused by the chronic low-grade systemic inflammation. As potent suppressors of inflammation, biologics were expected to influence HF development in RA. Unfortunately, case reports of HF in RA patients and non-RA HF studies have suggested that these drugs may even increase HF rates in RA. Aim: With this review we want to provide insight into the molecular mechanisms by which elevated cytokines, immune cell alterations and biologics influence myocardial function in RA patients. Beside preclinical data, clinical studies that assess the influence of biologics on HF development are reviewed. Results: Preclinical studies suggest a bidirectional role of the investigated cytokines (TNF-alpha, IL- 1, IL-6) on myocardial function. Common mechanisms of immune cell alterations in HF and RA have been observed in preclinical studies. High doses of infliximab in non-RA patients with HF were found to be harmful. The vast majority of retrospective studies suggest that TNF-alpha inhibitors do not increase the risk of HF development in RA patients. Nevertheless randomized controlled trials are missing and TNF-alpha inhibitors are contraindicated in RA patients with HF NYHA III/IV and should be used with caution in RA patients with HF NYHA I/II based on non-RA HF studies. Due to rare adverse events of HF, rituximab is contraindicated in RA patients with HF NYHA IV. Conclusion: Cytokines seem to have a bidirectional influence on HF development in RA. According to the published evidence it is unlikely that TNFalpha inhibitors substantially increase the risk of HF development in an RA population. Nevertheless they are contraindicated in RA patients with HF NYHA III/IV and should be used with caution in RA patients with HF NYHA I/II. The influence of anakinra, tocilizumab, rituximab and abatacept needs to be investigated in future studies. Keywords: Biologics, B-cells, chronic inflammation, cytokines, heart failure, rheumatoid arthritis, T-cells." @default.
• W829113430 created "2016-06-24" @default.
• W829113430 creator A5087986362 @default.
• W829113430 creator A5090856406 @default.
• W829113430 date "2015-05-14" @default.
• W829113430 modified "2023-09-25" @default.
• W829113430 title "Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients" @default.
• W829113430 doi "https://doi.org/10.2174/0929867322666150209160918" @default.
• W829113430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25666787" @default.
• W829113430 hasPublicationYear "2015" @default.
• W829113430 type Work @default.
• W829113430 sameAs 829113430 @default.
• W829113430 citedByCount "2" @default.
• W829113430 countsByYear W8291134302016 @default.
• W829113430 countsByYear W8291134302017 @default.
• W829113430 crossrefType "journal-article" @default.
• W829113430 hasAuthorship W829113430A5087986362 @default.
• W829113430 hasAuthorship W829113430A5090856406 @default.
• W829113430 hasConcept C126322002 @default.
• W829113430 hasConcept C164027704 @default.
• W829113430 hasConcept C17991360 @default.
• W829113430 hasConcept C197934379 @default.
• W829113430 hasConcept C203014093 @default.
• W829113430 hasConcept C2776914184 @default.
• W829113430 hasConcept C2777138892 @default.
• W829113430 hasConcept C2777575956 @default.
• W829113430 hasConcept C2778198053 @default.
• W829113430 hasConcept C2779338263 @default.
• W829113430 hasConcept C2780653079 @default.
• W829113430 hasConcept C71924100 @default.
• W829113430 hasConcept C8891405 @default.
• W829113430 hasConceptScore W829113430C126322002 @default.
• W829113430 hasConceptScore W829113430C164027704 @default.
• W829113430 hasConceptScore W829113430C17991360 @default.
• W829113430 hasConceptScore W829113430C197934379 @default.
• W829113430 hasConceptScore W829113430C203014093 @default.
• W829113430 hasConceptScore W829113430C2776914184 @default.
• W829113430 hasConceptScore W829113430C2777138892 @default.
• W829113430 hasConceptScore W829113430C2777575956 @default.
• W829113430 hasConceptScore W829113430C2778198053 @default.
• W829113430 hasConceptScore W829113430C2779338263 @default.
• W829113430 hasConceptScore W829113430C2780653079 @default.
• W829113430 hasConceptScore W829113430C71924100 @default.
• W829113430 hasConceptScore W829113430C8891405 @default.
• W829113430 hasIssue "16" @default.
• W829113430 hasLocation W8291134301 @default.
• W829113430 hasLocation W8291134302 @default.
• W829113430 hasOpenAccess W829113430 @default.
• W829113430 hasPrimaryLocation W8291134301 @default.
• W829113430 hasRelatedWork W1973470095 @default.
• W829113430 hasRelatedWork W1990433881 @default.
• W829113430 hasRelatedWork W1998340618 @default.
• W829113430 hasRelatedWork W2051597524 @default.
• W829113430 hasRelatedWork W2135038492 @default.
• W829113430 hasRelatedWork W2158479589 @default.
• W829113430 hasRelatedWork W2345141018 @default.
• W829113430 hasRelatedWork W2460286564 @default.
• W829113430 hasRelatedWork W2903934934 @default.
• W829113430 hasRelatedWork W407708035 @default.
• W829113430 hasVolume "22" @default.
• W829113430 isParatext "false" @default.
• W829113430 isRetracted "false" @default.
• W829113430 magId "829113430" @default.
• W829113430 workType "article" @default.